Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Classificação em ações #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Preço da ação
$58.70
Última sincronização: 2024-01-23
Valor de mercado
$2.98B
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Mirati Therapeutics, Inc. (MRTX)

Categoria

Histórico de desdobramentos de ações de Mirati Therapeutics, Inc. (MRTX)
As ações Mirati Therapeutics, Inc. (símbolo: MRTX) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Aug 27, 2026.
Uma ação MRTX comprada antes de Aug 27, 2026 equivaleria hoje a 0 ações MRTX.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH